Kanagawa, Japan

Tadayoshi Taniyama

This inventor holds 1 USPTO granted patent. Top assignee: Ssp Co. Ltd. Active years: 2004.


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tadayoshi Taniyama: Innovator in Imidazole Derivatives

Introduction

Tadayoshi Taniyama is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his work on imidazole derivatives. His innovative approach has led to advancements that may impact medical treatments.

Latest Patents

Taniyama holds a patent for imidazole derivatives or their salts. The patent describes pharmaceuticals containing these derivatives, which exhibit G-CSF-like activities. These compounds can serve as substitutes for G-CSF preparations, showcasing their potential therapeutic applications. The specific formula includes variations where R is lower alkyl, R is alkyl or aralkyl, and X is halogeno. This patent represents a significant step in pharmaceutical innovation.

Career Highlights

Tadayoshi Taniyama is associated with Ssp Co. Ltd., where he continues to develop his research and innovations. His work has garnered attention for its potential to enhance treatment options in various medical fields. With a focus on imidazole derivatives, Taniyama's contributions are paving the way for future advancements in pharmaceuticals.

Collaborations

Taniyama has collaborated with notable colleagues, including Hiromichi Eto and Sunao Takeda. Their combined expertise has likely contributed to the success of their projects and innovations in the pharmaceutical sector.

Conclusion

Tadayoshi Taniyama's work on imidazole derivatives exemplifies the impact of innovative thinking in pharmaceuticals. His contributions are significant, and they hold promise for future medical applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…